F-star Therapeutics, Inc. (FSTX)

NASDAQ: FSTX · IEX Real-Time Price · USD
6.39
+0.03 (0.47%)
Jun 24, 2022 4:00 PM EDT - Market closed
0.47%
Market Cap 137.75M
Revenue (ttm) 20.80M
Net Income (ttm) -33.79M
Shares Out 21.56M
EPS (ttm) -1.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,221,344
Open 6.30
Previous Close 6.36
Day's Range 6.07 - 6.45
52-Week Range 2.07 - 9.30
Beta n/a
Analysts Buy
Price Target 30.40 (+375.7%)
Earnings Date Aug 11, 2022

About FSTX

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 l... [Read more...]

Industry Biotechnology
IPO Date May 6, 2016
Employees 84
Stock Exchange NASDAQ
Ticker Symbol FSTX
Full Company Profile

Financial Performance

In 2021, FSTX's revenue was $21.17 million, an increase of 88.05% compared to the previous year's $11.26 million. Losses were -$31.28 million, 22.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for FSTX stock is "Buy." The 12-month stock price forecast is 30.4, which is an increase of 375.74% from the latest price.

Price Target
$30.4
(375.74% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SHAREHOLDER ALERT: Weiss Law Investigates F-star Therapeutics, Inc.

NEW YORK , June 24, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of F-star Therapeutics, Inc. ("F-star" or th...

F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm

Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating F-Star Therapeutics, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - June 24, 2022) - Rigrodsky Law, P.A. is investigating F-Star Therapeutics, Inc. ("F-Star") (NASDAQ: FSTX) regarding possible breaches of fiduciary duties and othe...

FSTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of F-star Therapeutics, Inc. Is Fair to Sharehol...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of F-star Therapeutics, Inc. (NASDAQ: FSTX) to invoX Pharma for $7.12 per share is fair to F-s...

Shareholder Alert: Ademi LLP investigates whether F-star Therapeutics, Inc. has obtained a Fair Price in its transact...

MILWAUKEE , June 23, 2022 /PRNewswire/ -- Ademi LLP is investigating F-star (NASDAQ:FSTX) for possible breaches of fiduciary duty and other violations of law in its transaction with invoX.  Click here t...

F-star Therapeutics Shares Are Rallying Today - Read Why

invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ: FSTX) for $7.12 per share.  The proposed acquisition values F-star at ap...

invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clin...

LONDON, June 23, 2022 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), focused on research and development (R&D) ...

Fstar Therapeutics, Inc. (FSTX) Reports Q1 Loss, Tops Revenue Estimates

Fstar Therapeutics, Inc. (FSTX) delivered earnings and revenue surprises of 9.52% and 10.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc.  (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicat...

Fstar Therapeutics, Inc. (FSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Fstar Therapeutics, Inc. (FSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generat...

F-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022

Unique Structure and Tetravalency of FS118 Is Required to Modulate LAG-3 Cell Surface Expression Unique Structure and Tetravalency of FS118 Is Required to Modulate LAG-3 Cell Surface Expression

F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update

Multiple Clinical Program Updates Expected in 2022

F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next gener...

F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next gener...

F-star Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next-genera...

F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology C...

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next genera...

F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021

First-in-Human Study of Company's CD137/PD-L1 Tetravalent Bispecific Antibody Expands into Tumor Specific Indications First-in-Human Study of Company's CD137/PD-L1 Tetravalent Bispecific Antibody Expand...

F-star Therapeutics to Host Virtual R&D Day on December 6, 2021

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next genera...

F-star Therapeutics (FSTX) Sees Hammer Chart Pattern: Time to Buy?

F-star Therapeutics (FSTX) has been struggling lately, but the selling pressure may be coming to an end soon.

F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference

Dr. Michelle Morrow to present on F-star's Proprietary Bispecific Platform including FS118, our LAG-3/PD-L1 Bispecific

Aerami Therapeutics Appoints Darlene Deptula-Hicks to its Board of Directors

DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc., a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced the app...

F-star Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Company to Host Conference Call Today at 9 a.m. EST

F-star Shares Rise On Bispecific Antibody Therapeutics Pact With Janssen

F-star Therapeutics Ltd (NASDAQ: FSTX) has entered into a license and collaboration agreement with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ). Under the terms of the agreement, F-star ...

F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021

Preclinical Data Indicates a Broad Therapeutic Window for F-star's First-in-Class Tetravalent Dual T cell Agonist Preclinical Data Indicates a Broad Therapeutic Window for F-star's First-in-Class Tetrav...